Evidence suggests that ACE inhibitors and angiotensin receptor blockers may improve prognosis in COVID-19 hypertensive patients

(Elsevier) Physicians, healthcare professionals, researchers, and patients are actively debating the potential influence of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients during the COVID-19 outbreak. In a new review published in Mayo Clinic Proceedings, a group of scientists who have been working on the frontlines fighting the deadly virus in Spain, Italy, and the United States, dissect the controversy in considerable detail, to explain the...